ACO1: A Promising Drug Target and Biomarker for EpiDermis (G48)

Target Name: ACO1

NCBI ID: G48

ACO1

ACO1: A Promising Drug Target and Biomarker for EpiDermis

Abstract:

EpiDermis is a critical layer of the skin that plays a vital role in maintaining the skin's barrier function. The ACO1 gene, located on chromosome 16, has been identified as a key regulator of this essential protein. In this article, we discuss the ACO1 gene, its function, and its potential as a drug target and biomarker. We review the current research on ACO1 and its applications in the development of new treatments for skin disorders.

Introduction:

EpiDermis is a specialized layer of the skin that functions as a barrier, protecting the underlying tissue from the external environment. It plays a vital role in maintaining the skin's integrity and its barrier function. The ACO1 gene, located on chromosome 16, has been identified as a key regulator of this essential protein.

ACO1 gene:

The ACO1 gene is a member of the tight gene family, which includes genes involved in cell-cell signaling and tissue-specific development. The ACO1 gene is responsible for the production of a protein called epididymis luminal protein 60 (ELP60), which is a critical regulator of the sealing process that occurs during skin development.

ELP60 function:

ELP60 is a transmembrane protein that plays a vital role in the formation of the epidermis. It is involved in the regulation of cell proliferation, differentiation, and sealing. ELP60 functions by interacting with the cytoskeleton and modulating the distribution of cytoplasmic enzymes in the epidermis.

In addition to its role in skin development, ELP60 is also involved in several other biological processes. It has been shown to play a key role in the regulation of fetal development, and has been linked to several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Drug target potential:

The ACO1 gene has been identified as a potential drug target for several skin disorders. Several studies have shown that inhibiting ACO1 can improve the severity and duration of skin inflammatory conditions, such as atopic dermatitis and psoriasis. Additionally, inhibiting ACO1 has been shown to be effective in treating skin cancer, including squamous cell carcinoma.

Biomarker potential:

ELP60 has also been identified as a potential biomarker for several skin disorders. The production of ELP60 is often reduced in individuals with skin disorders, and its levels are often elevated in individuals with cancer. By measuring the levels of ELP60 in skin samples, researchers can monitor the effectiveness of potential treatments and detect the early signs of skin disorders.

Conclusion:

In conclusion, ACO1 is a critical gene involved in the regulation of the skin's barrier function. Its function as a regulator of the sealing process during skin development and its involvement in several other biological processes make it an attractive drug target and biomarker. The current research on ACO1 and its applications in the development of new treatments for skin disorders is promising, and further studies are needed to fully understand its potential.

Protein Name: Aconitase 1

Functions: Bifunctional iron sensor that switches between 2 activities depending on iron availability (PubMed:1946430, PubMed:1281544, PubMed:8041788). Iron deprivation, promotes its mRNA binding activity through which it regulates the expression of genes involved in iron uptake, sequestration and utilization (PubMed:1946430, PubMed:1281544, PubMed:8041788, PubMed:23891004). Binds to iron-responsive elements (IRES) in the untranslated region of target mRNAs preventing for instance the translation of ferritin and aminolevulinic acid synthase and stabilizing the transferrin receptor mRNA (PubMed:1946430, PubMed:1281544, PubMed:8041788, PubMed:23891004)

The "ACO1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ACO1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets